ReviewCurrent treatment options in oncology2008
The emerging role of anti-angiogenic therapy for malignant glioma.
Review in Current treatment options in oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Use of bevacizumab in recurrent glioblastoma.CNS oncology · 2015Review
- Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.Brain : a journal of neurology · 2013Article
- Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.Neuro-oncology · 2012Article
- Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling.Developmental cell · 2011Article
- Association between body mass index and mortality in patients with glioblastoma mutliforme.Cancer causes & control : CCC · 2010Article
- Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.Molecular cancer therapeutics · 2010Article
- Article
- Expression sites of colligin 2 in glioma blood vessels.Brain pathology (Zurich, Switzerland) · 2010Article
- Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.The oncologist · 2010Article
- New therapies for recurrent glioblastomas.F1000 medicine reports · 2009Article
- Combining drugs and radiotherapy: from the bench to the bedside.Current opinion in neurology · 2009Review
- Antiangiogenic strategies for treatment of malignant gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
- Targeted transport of 125I-labeled antibody to GFAP and AMVB1 in an experimental rat model of C6 glioma.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009Article
- Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.Brain research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementAdults with glioblastoma multiforme (GBM), the most common primary brain tumor, have an unacceptably poor outcome with conventional cytotoxic therapies. Malignant gliomas are remarkably angiogenic, and vascular endothelial growth factor (VEGF) is the dominant pro-angiogenic factor. Recent clinical trials targeting VEGF signaling have achieved unprecedented rates of durable radiographic and clinical response, while also confirming adequate safety among recurrent malignant glioma patients. An array of additional clinical trials evaluating anti-angiogenic strategies are underway for both recurrent and newly diagnosed malignant glioma patients. Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy.
Indexed as
Identifiers
18256938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.